Skip to main content
Fig. 5 | BMC Cancer

Fig. 5

From: Recombinant human endostatin combined with radiotherapy inhibits colorectal cancer growth

Fig. 5

Effects of each treatment on tumor MVD. Expression of CD31 in each group at 16 days after treatment (a-d). a: control; b: endostatin; c: radiotherapy; d: radiotherapy with endostatin treatment; e: The MVDs of the four groups were compared by counting the numbers of CD31-positive microvessels in each group. a P < 0.05 versus control; b P < 0.05 versus radiotherapy (n = 8 per group). The MVD-CD31 values in the four groups were as follows: control group, 18.43 ± 1.58; endostatin group, 9.05 ± 1.46; radiotherapy group, 26.58 ± 1.86; and radiotherapy with endostatin treatment group, 11.22 ± 1.54. The MVD-CD31 value in the radiotherapy group was significantly higher than those in the other three groups (n = 8 per group, P < 0.05), and the MVD-CD31 values in the endostatin and radiotherapy with endostatin treatment groups were significantly decreased compared with that in the control group (n = 8 per group, P < 0.05) (200×)

Back to article page